Tag: proscar
SIGN UP FOR OUR NEWSLETTER


Quick Search

Reset

Avodart (dutasteride) & Proscar (finasteride)

Fri 1 Oct 2010

By: Mark Scholz, M.D. Prostate Oncology Specialists October 2010 Avodart® and Proscar® are FDA approved for the treatment of benign prostatic hyperplasia (BPH), the natural enlargement of the prostate that occurs with aging.  They are well-tolerated agents, except for occasional impotence or reduced libido that resolves when the treatment is stopped. Proscar and Avodart workRead More ›

What We Should Have Learned About Prostate Cancer (PC) in the Past 10 Years: Part Two

Fri 30 May 2008

by Stephen B. Strum, MD, FACP Medical Oncologist and PCRI Co-founder Ashland, OR Edited from PCRI Insights May, 2008 v 11.2 Editor’s Note: In the Part 1, Dr. Strum illustrated his thesis, “what we should have learned about PC prevention”, with a case study of the Prostate Cancer Prevention Trial (PCPT). Explanation of High-Grade PCRead More ›

What We Should Have Learned About Prostate Cancer (PC) in the Past 10 Years

Wed 27 Feb 2008

  by Stephen B. Strum, MD, FACP Medical Oncologist and PCRI Co-founder Ashland, OR Edited from PCRI Insights February, 2008 v 11.1   Overview The goal for this article is to present my views on the current status of the everyday care of the PC patient. This communication thus serves as a State of theRead More ›

The PCRI Views Regarding Testing for Prostate Cancer Using PSA as a Principal Marker

Tue 31 Aug 2004

  PCRI Insights August 2004 vol. 7, no. 3 PCRI Statement on Annual Testing for PC (The Basics) The Prostate Cancer Research Institute (PCRI) strongly supports annual testing for the early detection of prostate cancer. Effective testing combines both a prostate specific antigen (PSA) blood test and a digital rectal exam (DRE) for men, beginningRead More ›

Does Finasteride Alter the Pathology of the Prostate and Cancer Grading?

Sun 1 Feb 2004

By David G. Bostwick M.D., M.B.A., Bostwick Laboratories, Richmond, Virginia Reprinted from PCRI Insights February 2004 v7.1 Introduction One of the most important and popular forms of treatment for prostate cancer, androgen deprivation therapy (ADT), has been in use for more than 50 years. In the past two decades, new forms of androgen deprivation haveRead More ›